Ams Biotechnology

Water, Biotechnology Grade

42300008-1 1 gal
EUR 33.07

All Competitors Laboratories manufactures the ams biotechnology reagents distributed by Genprice. The Ams Biotechnology reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact All Competitors. Other Ams products are available in stock. Specificity: Ams Category: Biotechnology

True Blue

5mg Ask for price
Description: True Blue

True Blue

5(mg
EUR 635

True Blue

5x5(mg
EUR 2705

3M Sodium Acetate, pH5.2, Biotechnology Grade, 500ml

each Ask for price

JBS True Blue

300µl
EUR 13.7

True Blue Chloride

100mg
EUR 11200
Description: 71431-30-6

JBS True Blue

300 µl
EUR 16
Description: JBS True Blue

Serum / Plasma information

AMS-17

HY-146765 Get quote Ask for price
Description: AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders[1].

Biotin-Ova (323-339)

SB075 1
EUR 126.23
Description: Biotin-Ova (323-339) is the N-ter biotinylated version of Ova (323-339). Biotin-Ova (323-339) can be used in the analysis of antigen-specific T cells. Ovalbumin protein: Ova (323-339) is an epitope of interest of the egg white albumen, which is widely used in allergy research. Ovalbumin is a glycoprotein that is sufficiently large and complex to be mildly immunogenic. Indeed, it has been demonstrated that Ovalbumin contains B-cell epitopes which are recognized by specific IgE antibodies and CD4 T cell epitopes restricted by the MHC I-Ad molecule in mice and by HLA-D molecule in human.Applications of Ova (323-339):Ova (323-339) allows to study bindings of class II MHC-peptide and T-cell activation in PBMCs by ELISPOT assays. In fact, this method quantifies peptide epitope specificity and IFN-γ releasing effector cells. It has been shown that Ova (323-339) was responsible for 25-35% of T-cell response of isolated BALB/c mouse. An investigation has demonstrated that Ova and Ova (323-339) induced similar lung inflammation and a Th2-like dominant immune response in mouse model. Sequence: Biotin-ISQAVHAAHAEINEAGR

Amylase (AMS) Antibody

abx411112-1ml 1 ml
EUR 610.8

Amylase (AMS) Antibody

abx411113-1mg 1 mg
EUR 994.8

Amylase (AMS) Antibody

abx411114-1ml 1 ml
EUR 610.8

Amylase (AMS) Antibody

abx411112-100tests 100 tests
EUR 425

Amylase (AMS) Antibody

abx411114-100g 100 µg
EUR 425

Biotin-FluM1 (58-66)

SB074 1
EUR 182.33
Description: Biotin-FluM1 (58-66) is the N-ter biotinylated version of FluM1 (58-66). Biotin-FluM1 (58-66) can be used in the analysis of antigen-specific T cells.FluM1 (58-66):FluM1 (58-66) is a short part of the matrix protein of Influenza A virus which is the most abundant component of this enveloped virus localized under the viral lipid envelope. The GILGFVFTL epitope is highly conserved in Influenza A virus strains at a rate of 93% for 69 strains tested. Human Influenza epitopes may bind MHC molecules and then may be recognized by CD8+ cytotoxic T cells. Applications of FluM1 (58-66):FluM1 (58-66) is used to stimulate CTL responses in peripheral blood mononuclear cells (PBMCs). Then, ELISPOT assay is used to quantify peptide epitope specificity and IFN-γ releasing effector cells.FluM1 (58-66) has shown CTL responses qualified of immunodominant with restriction by HLA-A*02:01. It has also been detected CTL responses when FluM1 (58-66) is restricted by all HLA-C. Therefore, FluM1 (58-66) may help to understand the reaction of immune system against Influenza virus of each populations having different HLA type.FluM1 (58-66) has indeed prompted research to develop T-cell vaccine strategies capable of inducing specific CTL responses in patients upon immunization with Influenza M1 antigenic epitope. MVA-NP+M1 vaccine use GILGFVFTL epitope and is tested in clinical trial.Potential cross-reactivity with HIV-1 p17 Gag (77-85):Moreover, FluM1 (58-66) share similarities with HIV-1 p17 Gag (77-85) which can potentially show a cross-reactivity between these epitopes. It has been demonstrated a cross-reactivity and results suggest that immunity following infection by Influenza virus causes specific immune response to HIV-1 p17 Gag (77-85).Sequence: Biotin-GILGFVFTL

Biotin-Padre

SB183 1
EUR 210.38
Description: Pan HLA DR-binding epitope (PADRE) is a universal peptide that activates CD4+ T cells which can be used as an agonist adjuvant.

Biotin-MAGE-A1 (278-286)

SB077 1
EUR 112.2
Description: Biotin-MAGE-A1 (278-286) is the N-ter biotinylated version of MAGE-A1 (278-286). Biotin-MAGE-A1 (278-286) can be used in the analysis of antigen-specific T cells. MAGE-A1 protein:MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells. Applications of MAGE-A1 (278-286): MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.Sequence: Biotin-KVLEYVIKV

Biotin-MAGE-A2 (157-166)

SB078 1
EUR 112.2
Description: Biotin-MAGE-A2 (157-166) is the N-ter biotinylated version of MAGE-A2 (157-166). Biotin-MAGE-A2 (157-166) can be used in the analysis of antigen-specific T cells. MAGE-A2 protein: MAGE-A2 (157-166) is an epitope of Melanoma Antigen Gene A2 and is one of the most Cancer-Testis Antigens (CTA) overexpressed in tumors of different histological types, such as prostate cancer. Type of MAGE-A expressed in tumors cells varies according to the type of tumor. The expression of MAGE-A2 causes the proliferation of prostate cancer cells and decreases the chemosensitivity. Applications of MAGE-A2 (157-166):MAGE-A2 (157-166) is used to stimulate specific immune response, cytotoxic T cell response and to analyze the cytokine production in PBMCs by ELISPOT assay. In transgenic mouse, it has been demonstrated that MAGE-A2 (157-166) was capable of eliciting a CTL response presented by HLA-A*02:01 molecules. MAGE-A2 (157-166) has been reported to elicit CTL that could lyse tumor cell expressing both HLA-A*02:01 and MAGE-A2 by stimulation of peripheral blood mononuclear cells (PBMCs) with MAGE-A2 (157-166).Sequence: Biotin-YLQLVFGIEV

Biotin-ProTx-I

PTB001 0.1
EUR 409.06
Description: Ca channels

Chicken BIOTIn (B7) ELISA Kit

QY-E81562 96T
EUR 500

Biotin-NY-ESO-1 (157-165) C165V

SB076 1
EUR 112.2
Description: Biotin-NY-ESO-1 (157-165) – General analog epitope of tumor cellsBiotin-NY-ESO-1 (157-165) C165V peptide is the N-ter biotinylated version of NY-ESO-1 (157-165) C165V peptide. It can be used in the analysis of antigen-specific T cells. HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) native SLLMWITQC peptide, whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) C165V peptide application Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein, including SLLMWITQC, that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members, its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope, specificity, and cytokine production, like IFN-γ, SLLMWITQV variant peptide was used, as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover, SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.SB-PEPTIDE also offers the scrambled version of NY-ESO-1 (157-165) C165V peptide, as well as NY-ESO-1 (157-165) native peptide.

Human Biotinidase(BTD)ELISA Kit

QY-E01562 96T
EUR 433.2

Spike S biotin protein library

SB043-Biotin 0.5
EUR 2603.74
Description: Biotinylated version of the Spike (S) glycoprotein which corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.

Spike Omicron library Biotin

SB134 0.5
EUR 2602.81
Description: Overlaping biotin-peptide library of Spike Omicron mutant. 15 amino acids per peptide with offset 11. Each peptide is N-ter biotinylated. Purity crude. 1 peptide per well.